These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 34176253)

  • 1. Who Will Benefit from Charged-Particle Therapy?
    Kim KS; Wu HG
    Cancer Res Treat; 2021 Jul; 53(3):621-634. PubMed ID: 34176253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Technological Advances in Charged-Particle Therapy.
    Park JM; Kim JI; Wu HG
    Cancer Res Treat; 2021 Jul; 53(3):635-640. PubMed ID: 34176252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hadrontherapy for cancer. An overview of HTA reports and ongoing studies.
    Jefferson T; Formoso G; Venturelli F; Vicentini M; Chiarolla E; Ballini L
    Recenti Prog Med; 2019 Dec; 110(12):566-586. PubMed ID: 31909760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monte Carlo study of out-of-field exposure in carbon-ion radiotherapy: Organ doses in pediatric brain tumor treatment.
    Matsumoto S; Yonai S; Bolch WE
    Med Phys; 2019 Dec; 46(12):5824-5832. PubMed ID: 31603561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carbon-Ion Therapy: One More Step in the Endless Quest for the Ideal Dose Distribution.
    Schulz RJ; Kagan AR
    Int J Radiat Oncol Biol Phys; 2016 May; 95(1):561. PubMed ID: 27084666
    [No Abstract]   [Full Text] [Related]  

  • 6. Proton Beam Therapy and Carbon Ion Radiotherapy for Hepatocellular Carcinoma.
    Apisarnthanarax S; Bowen SR; Combs SE
    Semin Radiat Oncol; 2018 Oct; 28(4):309-320. PubMed ID: 30309641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physical and Biological Characteristics of Particle Therapy for Oncologists.
    Byun HK; Han MC; Yang K; Kim JS; Yoo GS; Koom WS; Kim YB
    Cancer Res Treat; 2021 Jul; 53(3):611-620. PubMed ID: 34139805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical applications of proton and carbon ion therapy.
    Rackwitz T; Debus J
    Semin Oncol; 2019 Jun; 46(3):226-232. PubMed ID: 31451309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secondary radiation measurements for particle therapy applications: prompt photons produced by
    Mattei I; Bini F; Collamati F; De Lucia E; Frallicciardi PM; Iarocci E; Mancini-Terracciano C; Marafini M; Muraro S; Paramatti R; Patera V; Piersanti L; Pinci D; Rucinski A; Russomando A; Sarti A; Sciubba A; Solfaroli Camillocci E; Toppi M; Traini G; Voena C; Battistoni G
    Phys Med Biol; 2017 Feb; 62(4):1438-1455. PubMed ID: 28114112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preliminary exploration of clinical factors affecting acute toxicity and quality of life after carbon ion therapy for prostate cancer.
    Zhang Y; Li P; Yu Q; Wu S; Chen X; Zhang Q; Fu S
    Radiat Oncol; 2019 Jun; 14(1):94. PubMed ID: 31164172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dosimetric comparison of advanced radiotherapy approaches using photon techniques and particle therapy in the postoperative management of thymoma.
    Haefner MF; Verma V; Bougatf N; Mielke T; Tonndorf-Martini E; König L; Rwigema JM; Simone CB; Uhlmann L; Eichhorn F; Winter H; Grosch H; Haberer T; Herfarth K; Debus J; Rieken S
    Acta Oncol; 2018 Dec; 57(12):1713-1720. PubMed ID: 30264630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Indications for Carbon Ion Radiotherapy.
    Mohamad O; Yamada S; Durante M
    Clin Oncol (R Coll Radiol); 2018 May; 30(5):317-329. PubMed ID: 29402598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing the dosimetric impact of interfractional anatomical changes in photon, proton and carbon ion radiotherapy for pancreatic cancer patients.
    Houweling AC; Crama K; Visser J; Fukata K; Rasch CR; Ohno T; Bel A; van der Horst A
    Phys Med Biol; 2017 Apr; 62(8):3051-3064. PubMed ID: 28252445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The 20th Gray lecture 2019: health and heavy ions.
    Blakely EA
    Br J Radiol; 2020 Nov; 93(1115):20200172. PubMed ID: 33021811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imaging issues specific to hadrontherapy (proton, carbon, helium therapy and other charged particles) for radiotherapy planning, setup, dose monitoring and tissue response assessment.
    Thariat J; Hérault J; Beddok A; Feuvret L; Dauvergne D; Gérard M; Balosso J; Noël G; Valable S
    Cancer Radiother; 2020 Aug; 24(5):429-436. PubMed ID: 32247687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of subsequent primary cancers after carbon ion radiotherapy, photon radiotherapy, or surgery for localised prostate cancer: a propensity score-weighted, retrospective, cohort study.
    Mohamad O; Tabuchi T; Nitta Y; Nomoto A; Sato A; Kasuya G; Makishima H; Choy H; Yamada S; Morishima T; Tsuji H; Miyashiro I; Kamada T
    Lancet Oncol; 2019 May; 20(5):674-685. PubMed ID: 30885458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High control rates of proton- and carbon-ion-beam treatment with intensity-modulated active raster scanning in 101 patients with skull base chondrosarcoma at the Heidelberg Ion Beam Therapy Center.
    Mattke M; Vogt K; Bougatf N; Welzel T; Oelmann-Avendano J; Hauswald H; Jensen A; Ellerbrock M; Jäkel O; Haberer T; Herfarth K; Debus J; Uhl M
    Cancer; 2018 May; 124(9):2036-2044. PubMed ID: 29469932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes of carbon-ion radiotherapy for patients with locoregionally recurrent nasopharyngeal carcinoma.
    Hu J; Huang Q; Gao J; Guan X; Hu W; Yang J; Qiu X; Chen M; Kong L; Lu JJ
    Cancer; 2020 Dec; 126(23):5173-5183. PubMed ID: 32931035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salvage Carbon-Ion Radiation Therapy For Locoregionally Recurrent Head and Neck Malignancies.
    Gao J; Hu J; Guan X; Yang J; Hu W; Kong L; Lu JJ
    Sci Rep; 2019 Mar; 9(1):4259. PubMed ID: 30862843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health Technology Assessment of Carbon-ion Beam Radiotherapy: A Systematic Review of Clinical Effectiveness and Safety for 54 Oncological Indications in 12 Tumour Regions.
    Goetz G; Mitic M; Mittermayr T; Wild C
    Anticancer Res; 2019 Apr; 39(4):1635-1650. PubMed ID: 30952702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.